Vericel Corporation (NASDAQ: VCEL) saw its stock price surge 8.47% in pre-market trading following the release of its impressive third-quarter 2025 financial results. The company significantly outperformed market expectations, demonstrating strong growth and profitability across key metrics.

The biotechnology firm reported Q3 revenue of $67.503 million, handily beating the IBES estimate of $64.6 million. Earnings per share (EPS) came in at $0.10, surpassing the anticipated loss of $0.01 per share. This stellar performance was underpinned by a robust gross profit of $49.585 million and an impressive gross margin of 73.5%.

Vericel's profitability metrics were equally strong, with net income reaching $5.074 million and adjusted EBITDA hitting $16.996 million, representing a 25% margin. Looking ahead, the company provided an optimistic full-year revenue outlook of $272-276 million, further boosting investor confidence. The combination of better-than-expected results and positive future guidance appears to be driving the significant pre-market rally in Vericel's stock price.